Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Conclusion: This study shows that OLM and AZ reduced BP and proteinuria without decreasing eGFR in Japanese hypertensive patients with CKD in the setting of daily clinical practice.
PMID: 22020401 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)